[Side branch occlusion rate at sites of overlapping sirolimus- or paclitaxel-eluting stents for treating long coronary lesions].
OBJECTIVE
To compare side branch occlusion rate at sites of overlapping sirolimus- or paclitaxel-eluting stents in treating long coronary lesions.


METHODS
We retrospectively reviewed the PCI CD and medical records of PCI 141 patients with at least one stent overlapping for long coronary lesion in our institute from January 2004 to October 2007. The side branches occlusion was documented and analyzed.


RESULTS
The study population were consisted of 141 patients that there were 115 man, and 26 women, who got 297 stents. There were 154 side branch vessels been observed. Side branch occlusion rate was 24.6% in Cypher group and 31.6% in TAXUS (P > 0.05), side branch TIMI flow decrease rate on overlapping region was 26.3% in Cypher group and 68.4% in TAXUS group (P > 0.05). A logistic regression model analysis show that the significant risk factors for side branch occlusion is the diameter and ostial occlusion of side branch.


CONCLUSIONS
Side branch occlusion rate and TIMI flow decrease rate were similar on overlapping region in patients treated with Cypher or TAXUS stents for long coronary lesions. The significant predictors for side branch TIMI flow decrease are the diameter and ostial occlusion of side branch.
Xie
Hong-zhi
HZ
Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Fang
Quan
Q
Zhang
Shu-yang
SY
Shen
Zhu-jun
ZJ
Zeng
Yong
Y
Wang
Chong-hui
CH
Jin
Xiao-feng
XF
Liu
Zhen-yu
ZY
Shen
Jian-zhong
JZ
D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D019917:Blood Vessel Prosthesis Implantation; D003324:Coronary Artery Disease / Q000628:therapy*; D023903:Coronary Restenosis / Q000209:etiology*; D003331:Coronary Vessels; D054855:Drug-Eluting Stents; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage; D012189:Retrospective Studies; D020123:Sirolimus / Q000008:administration & dosage; D016896:Treatment Outcome
D017239:Paclitaxel; D020123:Sirolimus